• Cimetidine in Cancer and BBB Research Context

  2026-10-06

  This overview places Cimetidine in the context of histamine-2 receptor pharmacology, cancer research, and contemporary blood-brain barrier modeling. It separates supplier descriptions and mechanistic hypotheses from findings reported in a 2025 surrogate BBB study, while outlining evidence strength, translational relevance, and key limits on applying that model to Cimetidine specifically.

• Hsa_circ_0001944, FXR/TLR4, and Ferroptosis

  2026-10-05

  A 2025 Toxics study links reduced hsa_circ_0001944 with altered FXR/TLR4 signaling, ferroptosis-related markers, and collagen formation in NiONP-exposed LX-2 cells. Its findings position the circRNA–FXR axis as a mechanistic hypothesis for toxicant-associated hepatic stellate-cell activation, while remaining limited by its cell-model design and marker-based evidence.

• BMS-345541 in NF-κB and Angiogenesis Research

  2026-10-05

  BMS-345541 is a selective IKK-1/IKK-2 inhibitor used as a pharmacological tool for studying NF-κB signaling. This overview examines its research context through a 2020 study of thymosin-β4, Notch/NF-κB signaling, and angiogenesis in critical limb ischemia models. It distinguishes supplier-reported properties from findings in the primary literature, evaluates the strength of pathway-based evidence, and outlines limitations affecting interpretation in inflammation research, vascular biology, and cancer research.

• Coelenterazine: From ROS Signal to Translation

  2026-10-04

  Coelenterazine can connect luciferase-compatible reporting with chemiluminescent detection of selected reactive oxygen species, but translational value depends on separating substrate chemistry from biological interpretation. This thought-leadership article links that challenge to Greenwood and colleagues’ brain–kidney study of liraglutide, highlighting how multisystem validation can make oxidative stress measurement more credible.

• THBS1 in Laryngeal Cancer: Evidence and Implications

  2026-10-03

  The reference study combines transcriptomic datasets, machine-learning feature selection, survival analysis, pathway evaluation, and cell-based assays to identify THBS1 as a prognostic biomarker and possible therapeutic vulnerability in laryngeal cancer. Its findings connect high THBS1 expression with tumor-associated biology and an immune-suppressive transcriptomic context, while also highlighting the need for prospective clinical validation and more direct mechanistic studies.

• NF-κB/miR-202-5p/HMGB2 in Septic AKI

  2026-10-02

  The reference study identifies an adaptive NF-κB/miR-202-5p/HMGB2 feedback loop that limits renal inflammation and tubular injury during sepsis-associated acute kidney injury. Its combination of in vivo and LPS-stimulated tubular-cell models with ChIP, luciferase, miRNA, and siRNA experiments provides a mechanistic framework for interpreting NF-κB-dependent cytokine regulation in septic AKI.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-10-01

  BRD4770 is a G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence and cancer-cell growth phenotypes. This workflow translates its reported PANC-1 activity and the c-MYC/G9a research framework into practical dosing, readout, and troubleshooting strategies.

• 25-Hydroxycholesterol–Lysosomal AMPK Axis in TAMs

  2026-10-01

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that accumulates in tumor-associated macrophage lysosomes and activates AMPKα through a GPR155–mTORC1 mechanism. The study connects lysosomal lipid handling to STAT6-dependent ARG1 expression, macrophage immunosuppression, T-cell exclusion, and improved anti-PD-1 responses after CH25H targeting.

• Mycophenolic Acid in Whole-Blood Assays

  2026-09-30

  Use Mycophenolic acid as a controlled dehydrogenase inhibitor to connect nucleotide metabolism with cytokine behavior in fresh whole-blood assays. This workflow emphasizes matched donor controls, practical stock preparation, pilot concentration design, and troubleshooting for reproducible immunometabolism research.

• N-octanoyl-L-Homoserine lactone: Host-Cell Assays

  2026-09-30

  N-octanoyl-L-Homoserine lactone, or C8-HSL, connects bacterial quorum sensing with host-cell signaling. This guide focuses on causal assay design, controls, and the translational limits of studying microbial signals in cancer and infection biology.

• BMS-345541: From IKK Inhibition to Assay Insight

  2026-09-29

  BMS-345541 is an IKK-1/IKK-2 inhibitor that enables controlled analysis of NF-κB-dependent inflammation, angiogenesis, and cell death. This article focuses on how to translate mechanistic evidence into better assay design, especially in vascular and cytokine-driven models.

• D-Luciferin sodium salt: Assay Reliability

  2026-09-29

  A scenario-based guide to using D-Luciferin sodium salt, SKU B8311, in ATP-dependent bioluminescence assays for cell viability, metabolism, and oncology research. It addresses substrate handling, controls, interpretation, and practical vendor-selection criteria without overstating unverified performance claims.

• N2703 in Adipose-Neural Axis Research

  2026-09-28

  Use 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) as a flexible perturbation reagent for testing adipose-neural signaling in cardiac cell models. This guide emphasizes controlled dosing, orthogonal readouts, and troubleshooting rather than assuming a target mechanism that still requires validation.

• Nanoparticle Sulforaphane Targets NSCLC Metastasis

  2026-09-28

  The study identifies SPI1-driven miR-616-5p regulation as a contributor to non-small cell lung cancer (NSCLC) cell migration and invasion, and reports that sulforaphane can inhibit this pathway. A hyaluronic acid- and folic acid-modified mesoporous silica nanoparticle formulation improved sulforaphane delivery and anti-metastatic effects in NSCLC xenograft models, providing a preclinical strategy to address the compound’s stability limitations.

• Beyond Pathway Labels: A 83-01 in Biliary Research

  2026-09-27

  A 83-01 offers a precise way to test TGF-β/Smad contributions alongside WNT-driven biliary growth. Here, we translate recent extrahepatic bile duct findings into a cautious, testable strategy for translational researchers.

8477 records 1/566 page Next 12345 下5页 Last page